Wed, May 14, 6:11 PM (60 days ago)
**Harvard Apparatus Regenerative Technology, Inc. (HART) - Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** Product revenue decreased by 21% to $45,000 in Q1 2025 from $57,000 in Q1 2024, primarily due to wholesale pricing to a distributor. - **Profit Margins:** Gross profit margin decreased due to wholesale pricing compared to retail pricing in the prior quarter. - **Operating Loss:** Operating loss narrowed by 18% to $1,659,000 in Q1 2025 from $2,030,000 in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $758,000 in Q1 2025, compared to $960,000 in Q1 2024. - **Cash Position:** Cash and cash equivalents decreased to $1,728,000 at the end of Q1 2025 from $2,486,000 at the end of Q1 2024. **Earnings Changes and Trends:** - **Research and Development:** Expenses decreased by 28% to $601,000 due to reduced clinical and preclinical trial activities. - **Sales and Marketing:** Expenses decreased by 91% to $10,000 due to reduced employee compensation. - **General and Administrative:** Expenses decreased by 4% to $1,071,000 due to reduced share-based compensation. - **Interest Income:** Increased to $13,000 in Q1 2025 from $0 in Q1 2024. - **Interest Expense:** Decreased to $2,000 in Q1 2025 from $9,000 in Q1 2024. **Future Operations and Uncertainties:** - **Going Concern:** HART has substantial doubt about its ability to continue as a going concern due to accumulated losses and the need for additional financing. - **Funding:** HART plans to seek additional capital through equity offerings, debt financings, research grants, or strategic collaborations. - **Clinical Trials:** Delays in patient recruitment for the ongoing clinical trial may impact the timeline for regulatory approval. - **Market Risk:** HART is exposed to market risks related to changes in interest rates, foreign currency exchange rates, and equity prices. **Segment Performance:** - **Regenerative Biotech:** Focused on developing regenerative medicine treatments, with significant operating losses. - **Consumer Health Products:** Generated all revenue in Q1 2025, with a small net loss. **Ticker:** HART is not listed on any exchange, so there is no ticker symbol provided.